Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease

Published:2020-03-09 Issue:1 Volume:112 Page:115-117
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Mori Jinichi,Oshima Kumi,Tanimoto Tetsuya,Ishizuka Hikari,Kimura Shinya,Miura Masatomo,Takahashi Naoto

Funder

Grant-in-Aid for Scientific Research

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-020-02846-5.pdf

Reference8 articles.

1. Miura M, Takahashi N. Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC-UV or LC-MS/MS methods. Drug Metab Pharmacokinet. 2016;31:12–20.

2. Christopher LJ, Cui D, Li W, Barros A, Arora VK, Zhang H, et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008;36:1357–64.

3. Mizuta S, Sawa M, Tsurumi H, Matsumoto K, Miyao K, Hara T, et al. Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study. Int J Clin Oncol. 2018;23:980–8.

4. Rousselot P, Mollica L, Etienne G, Bouchet S, Guerci A, Nicolini FE, et al. Pharmacologic monitoring of dasatinib as first line therapy in newly diagnosed chronic phase chronic myelogenous leukemia (CP-CML) identifies patients at higher risk of pleural effusion: a sub-analysis of the OPTIM-dasatinib trial. Blood. 2012;120:3770.

5. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4:1065–74.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacology of Tyrosine Kinase Inhibitors;Clinical Journal of the American Society of Nephrology;2023-12-11

2. High throughput LC/ESI-MS/MS method for simultaneous analysis of 20 oral molecular-targeted anticancer drugs and the active metabolite of sunitinib in human plasma;Heliyon;2023-06

3. Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies;Medical Oncology;2023-05-10

4. Management of cancer treatments in hemodialysis patients;Bulletin du Cancer;2023-03

5. How to manage CML patients with comorbidities;Hematology;2020-12-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3